#United States #Diamond Bar, California #IFLI #Mehrdad Mobasher #Carol O'Hear

Institute for Follicular Lymphoma Innovation Announces New Leadership

In a significant move aimed at accelerating advancements in the treatment of follicular lymphoma, the Institute for Follicular Lymphoma Innovation (IFLI) has appointed Dr. Mehrdad Mobasher and Dr. Carol O'Hear as its new Executive Partners. This announcement marks a strategic milestone for IFLI, a non-profit organization dedicated to supporting the development of innovative therapies for patients battling this complex disease.

A Vision for Change

David McCullagh, Managing Director of IFLI, expressed great confidence in the new appointees, noting their extensive experience and remarkable track records in drug development. He stated, "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise. Their knowledge will greatly enhance our mission to revolutionize treatment options for follicular lymphoma patients."

Dr. Mobasher brings over 20 years of acclaimed leadership in hematology and oncology to IFLI. Before joining, he served as the Chief Medical Officer at BeOne (formerly BeiGene), where he played a pivotal role in the global rollout of zanubrutinib. His experience also includes notable leadership at Zai Lab and Corvus Pharmaceuticals, as well as significant contributions at Genentech, where his efforts on venetoclax were instrumental. Mobasher holds an M.D. from Tehran University, complemented by an M.P.H. from The University of Michigan.

In his own words, Dr. Mobasher expressed enthusiasm about his role at IFLI: "I am honored to join IFLI, an organization with a truly unique vision and commitment to advancing innovation for patients with follicular lymphoma. I look forward to collaborating with the team and partners across the ecosystem to accelerate our collective progress toward transformative therapies."

Dr. Carol O'Hear's Contribution

Dr. Carol O'Hear complements Dr. Mobasher's expertise with her own impressive background in drug discovery and clinical development. Currently the SVP of Clinical Development and Chief Medical Officer at Exelixis, Dr. O'Hear has previously made significant strides at Gilead and Genentech focusing on oncology. Her firsthand experience with product expansions and an in-depth understanding of drug development positions her as a key asset for IFLI’s ongoing mission.

She remarked, "Working with IFLI is an exciting opportunity to focus on what motivates me the most—identifying promising scientific discoveries and translating them into meaningful treatments for patients. I admire IFLI's strategic vision and dedication to impactful innovation, and I’m eager to contribute to the team's efforts in advancing novel therapies that can truly change lives."

IFLI’s Commitment to Innovative Research

The Institute for Follicular Lymphoma Innovation stands as a beacon of hope for those affected by follicular lymphoma, a condition often marked by its complexity and challenges in treatment. The foundation is dedicated to advancing innovative treatment options, supporting cutting-edge research, and fostering collaboration among leading scientists and institutions.

With a focus on understanding the biology of follicular lymphoma and developing novel therapeutics and biomarkers, IFLI deploys its resources through grants and venture philanthropic investments. This strategic approach not only accelerates research but also promotes data sharing and knowledge exchange among researchers.

Dr. Mobasher and Dr. O'Hear's appointments are expected to strengthen IFLI's efforts to create a impactful environment for innovation, enhancing relationships with life sciences companies, and guiding portfolio companies to deliver transformative therapies to patients in need.

Conclusion

As IFLI embarks on this new chapter with its exemplary leaders at the helm, the organization emphasizes its unwavering commitment to driving progress in the treatment of follicular lymphoma. Their extensive backgrounds and unwavering dedication promise a future where innovative therapies become a reality for patients across the globe.